Medtronic Canada Recognized as one of Canada's Top 100 Employers for 2021

COVID-19 Response, Mission Focus, and a Comprehensive Health and Wellness Package Among Reasons for Selection

Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT), announced today that it has been recognized by MediaCorp. as one of Canada's Top 100 Employers for 2021, for the seventh time.

Medtronic Canada ULC Logo (CNW Group/Medtronic Canada ULC)

Canada's Top 100 Employers is a national competition to determine which employers lead their industries in offering exceptional workplaces and the most progressive and forward-thinking programs for their employees.

Throughout this year's global pandemic, Medtronic has prioritized ongoing communication, mental wellness, and its employees' health and safety. Since March, 94% of employees have been working from home and relied on ongoing leadership communication to stay connected. The company's president, Neil Fraser , initially held weekly (now bi-weekly) all-employee calls, which included a prominent public health physician to address the latest COVID-19 related updates and respond to employees' questions and concerns. "We recognized that throughout all of the noise, employees valued our weekly touchpoints as an occasion to keep connected as a company and to support each other," said Fraser.

Employees have continued to live the company's Mission — to alleviate pain, restore health, and extend life.

Nicole Martel , a field service representative, agrees. Martel is on the road four days a week throughout Ontario . She services and repairs Medtronic ventilators — the products that have been at the forefront in the management of some hospitalized COVID-19 patients. Martel supports all of Ontario and when airline flights were cancelled because of the COVID-19 pandemic, she had to drive up to 12 hours to support customers.

The fifth tenet of the company's Mission — to recognize the personal worth of all employees — is something that resonates with Martel. "Throughout the pandemic, I never felt alone," added Martel. "Through Neil's weekly calls, my amazing team, and the health programs that were offered, I received everything I needed to continue to do my job."

In May 2020 , the company added a virtual health care plan that employees could benefit from, including online physician consultations. The company also collaborated with the Canadian Mental Health Association and implemented Not Myself Today® as an additional tool to help support employees' mental well-being; Medtronic also encourages physical wellness through live online fitness and meditation classes.

Medtronic is the largest medical device employer in Canada and Medtronic technologies are used to address nearly 70 medical conditions. Last year alone, Medtronic innovations benefitted 75 million people globally — that's two people every second.

About Medtronic Canada ULC
Proudly serving Canadian healthcare for over 50 years, Medtronic Canada ULC ( www.medtronic.ca ), is a subsidiary of Medtronic plc, one of the world's largest medical technology, services, and solutions companies — alleviating pain, restoring health, and extending life for millions of people around the world. Serving physicians, hospitals, and patients across the country, Medtronic Canada ULC is headquartered in Brampton, Ontario , with regional offices in Montreal and Vancouver , and a Medtronic Resource Centre in Surrey, BC . The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Top 100 Employers (CNW Group/Medtronic Canada ULC)

SOURCE Medtronic Canada ULC

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/November2020/13/c3117.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Medtronic moves for patent infringement litigation to resume

Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

2023 Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Glen Eagle Resources Inc.

(TheNewswire)

Glen Eagle Resources Inc.

Glen Eagle Resources Inc. ( TSX VENTURE: GER) ("Glen Eagle" or the "Company")  announces that the court has homologated the judgement, ordering the Company to pay Gem Yield Bahamas Limited a compensation of $1,875,895 dollars including interest and $90,000 in penalty

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 21, 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
CardieX Limited

Funding Commitment Agreement Update

CARDIEX Limited (ASX:CDX) (CARDIEX, the Company) provides an update on the Funding Commitment Agreement (FCA) with C2 Ventures Pty Limited (C2V, owned by Directors Niall Cairns and Craig Cooper) as announced on 8 November 2023.

Keep reading...Show less

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

  • New pharmacokinetic data demonstrate Virtue ® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable remaining polymer within 90 days of balloon delivery
  • AVIM therapy presentation highlighted recent clinical results showing favorable hemodynamic effects and long-term reduction in 24-hour ambulatory systolic blood pressure, as well as the design of the BACKBEAT global pivotal study now enrolling in collaboration with Medtronic, plc (NYSE:MDT)

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced two oral presentations were given at the Cardiovascular Research Technologies ("CRT") 2024 Meeting in Washington, D.C. One presentation featured new preclinical pharmacokinetic ("PK") data on Virtue ® Sirolimus AngioInfusion Balloon ("SAB"), a novel drug-eluting balloon angioplasty system designed to deliver a proprietary, extended-release formulation of sirolimus, SirolimusEFR™ to the vessel wall during balloon angioplasty without any coating on the balloon surface. A second presentation featured recently reported clinical data on atrioventricular interval modulation ("AVIM") therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure. The AVIM presentation also outlined the design of the currently enrolling BACKBEAT global pivotal study evaluating AVIM therapy in hypertensive pacemaker patients in collaboration with Medtronic.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×